Výsledky vyhledávání

Akademický článek

A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective

Autor: Baker CL, Ding Y, Ferrufino CP, Kowal S, Tan J, Subedi P

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 359-370 (2018)

Christine L Baker,1 Yao Ding,2 Cheryl P Ferrufino,2 Stacey Kowal,2 Jenen Tan,3 Prasun Subedi1 1Patient & Health Impact, Pfizer, Inc, New York, NY, USA; 2Health Economics & Outcomes Research, Real World Evidence Solutions, IQVIA, Fairfax, VA, USA; 3IQ

Externí odkaz: https://doaj.org/article/d333137cd5a548abbc42c7845a38bce0

Zobrazit plný text záznamu

Akademický článek

A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial

Autor: Baker CL, Pietri G

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 67-74 (2018)

Christine L Baker,1 Guilhem Pietri2 1Pfizer Inc., New York, NY, USA; 2Data Pyxis Ltd., St Albans, UK Background: The cost-effectiveness of varenicline has been demonstrated in the US health care setting using the Benefits of Smoking Cessation on Outc

Externí odkaz: https://doaj.org/article/ff126102019d480c9dc9c2b81fb1a4c3

Zobrazit plný text záznamu

Akademický článek

COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members

Autor: Pasquale MK, Xu Y, Baker CL, Zou KH, Teeter JG, Renda AM, Davis CC, Lee TC, Bobula J

Publikováno v: International Journal of COPD, Vol 2016, Iss default, Pp 111-121 (2016)

Margaret K Pasquale,1 Yihua Xu,1 Christine L Baker,2 Kelly H Zou,3 John G Teeter,4 Andrew M Renda,5 Cralen C Davis,1 Theodore C Lee,6 Joel Bobula2 1Comprehensive Health Insights, Inc., Humana Inc., Louisville, KY, 2Outcomes and Evidence, Global Healt

Externí odkaz: https://doaj.org/article/7dd93f684bd24f9590889cb1749786c6

Zobrazit plný text záznamu

Akademický článek

Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data

Autor: Baker CL, Zou KH, Su J

Publikováno v: International Journal of COPD, Vol 2014, Iss default, Pp 431-439 (2014)

Christine L Baker,1 Kelly H Zou,1 Jun Su21Pfizer Inc., New York, NY, USA; 2Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USABackground: Treatment of stable chronic obstructive pulmonary disease (COPD) with long-acting bronchodilator (LAB

Externí odkaz: https://doaj.org/article/c0c115fd602641188f7cdfaa98008ec6

Zobrazit plný text záznamu

Akademický článek

Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification

Autor: Price DB, Baker CL, Zou KH, Higgins VS, Bailey JT, Pike JS

Publikováno v: International Journal of COPD, Vol 2014, Iss default, Pp 551-561 (2014)

David B Price,1 Christine L Baker,2 Kelly H Zou,3 Victoria S Higgins,4 James T Bailey,4 James S Pike4 1University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK; 2Pfizer Inc, Outcomes and Evidence, Global Health and Value, New York, U

Externí odkaz: https://doaj.org/article/6044a7f6b0f7481aa3336db7df8ba04d

Zobrazit plný text záznamu

Akademický článek

EE243 Targeted Literature Review of Cost-Effectiveness Analyses in Sickle Cell Disease: Identifying the Optimal Modeling Approach for Therapies Targeting Sickle Hemoglobin Polymerization

Autor: Taylor, A, Stargardter, M, Baker, CL, Barcelos, GT, Milev, S

Publikováno v: In Value in Health June 2024 27(6) Supplement:S101-S101

Zobrazit plný text záznamu

Akademický článek

EE137 Economic Burden for Adults With Sickle Cell Disease and Matched Controls in the United States: Retrospective Analysis of a Commercial Insurance Database

Autor: Barcelos, GT, Peixoto, T, Alvir, J, Lingohr-Smith, M., Lin, J, Baker, CL

Publikováno v: In Value in Health June 2024 27(6) Supplement:S82-S82

Zobrazit plný text záznamu

Akademický článek

Risk assessment of readmissions following an initial COPD-related hospitalization

Autor: Baker CL, Zou KH, Su J

Publikováno v: International Journal of COPD, Vol 2013, Iss default, Pp 551-559 (2013)

Christine L Baker,1 Kelly H Zou,1 Jun Su2 1Pfizer Inc, New York, NY, USA; 2Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a leading cause of hospitalizat

Externí odkaz: https://doaj.org/article/9f4abf24e0664fcf96af3f2acdd0e16f

Zobrazit plný text záznamu

Akademický článek

Adjusting for COPD severity in database research: developing and validating an algorithm

Autor: Goossens LMA, Baker CL, Monz BU, Zou KH, Rutten-van Mölken MPMH

Publikováno v: International Journal of COPD, Vol 2011, Iss default, Pp 669-678 (2011)

Lucas MA Goossens1, Christine L Baker2, Brigitta U Monz3, Kelly H Zou2, Maureen PMH Rutten-van Mölken11Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; 2Pfizer Inc, New York City, NY, USA; 3Boehringer Inge

Externí odkaz: https://doaj.org/article/5bc43a2de3994fae81e38d8222da6e86

Zobrazit plný text záznamu

Akademický článek

Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease

Autor: Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, Shah H

Publikováno v: Patient Preference and Adherence, Vol 2011, Iss default, Pp 375-388 (2011)

Rachel Halpern1, Christine L Baker2, Jun Su3, Kimberly B Woodruff2, Ryne Paulose-Ram2, Victoria Porter1, Hemal Shah41Health Economics and Outcomes Research, OptumInsight, Eden Prairie, MN, USA; 2Global Market Access, Primary Care Business Unit, Pfize

Externí odkaz: https://doaj.org/article/e3cc85499b72473ea894f907ba6226d8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání